Friday, December 9, 2011

Some Emerging or Submerging New Therapeutic Agents in Rheumatoid Arthritis

Though I had had a look at the new kids on the block, here’s some more information on emerging or submerging new therapeutic agents in rheumatoid arthritis. The list is incomplete, which also depends on the definition of new.

Atacicept, a recombinant fusion protein designed to inhibit B cells has been studied in patients with rheumatoid arthritis and an inadequate response to methotrexate, but failed to meet primary endpoint (ACR20-CRP response) in a phase 2 study and will not be further studied in rheumatoid arthritis.

Atacicept BMS-945429, an aglycosylated, humanized MAB to IL-6, is still studied in a phase 2B in rheumatoid arthritis, no study published yet.

BT-061, a humanized Treg activating agonistic MAB, is studied, no study published yet.

S.B. Cohen and colleagues looked at pamapimod, a p38 MAP kinase inhibitor, but the study showed that pamapimod was not as effective as MTX in the treatment of active rheumatoid arthritis.

Ocrelizumab didn’t show aclear advantage over rituximab and concerns about serious and opportunistic infection rates has led to the cessation of the programme for RA and SLE, though the patients were still followed.

I’ll have a look into B-cell-depletion and new candidates to do so later.

No comments:

Post a Comment